<DOC>
	<DOC>NCT00747071</DOC>
	<brief_summary>This clinical study is designed to evaluate the safety and efficacy of oral administration of the food additive colostrum derived antibodies to Clostridium difficile for prevention of Clostridium difficile associated disease (CDAD).</brief_summary>
	<brief_title>Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Age 18 or older Written informed consent At least 3 unformed or watery stools in each of the 2 previous 24 hour periods. Confirmed diagnosis of C. difficile associated diarrhea Pregnant or breast feeding women Known allergy to milk or milk products Other etiology of diarrhea Active or Chronic conditions: IBD, short bowel syndrome, ischemic colitis Ileus Pseudomembranous colitis White blood count &gt; 50,000 Blood in stools Laxatives or motility drugs within 12 hours Inability to participate in adequate follow up Clinically unstable Investigator deems unsuitable Immune suppression (disease or treatment) GI surgery Past intestinal parasites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>diarrhea</keyword>
	<keyword>colostrum</keyword>
</DOC>